Condition
Leukodystrophy, Globoid Cell
Total Trials
4
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Suspended1
Withdrawn1
Completed1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04771416Phase 1SuspendedPrimary
Study of Safety, Tolerability and Efficacy of PBKR03 in Pediatric Subjects With Early Infantile Krabbe Disease
NCT02254863Phase 1Recruiting
UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
NCT01093105WithdrawnPrimary
An Observational Study of Pediatric Subjects With Globoid Cell Leukodystrophy (GLD)
NCT00006057Completed
Diagnostic and Screening Study of Genetic Disorders
Showing all 4 trials